Week in Review Yantai\'s MabPlex Raises $59 Million to Expand CDMO Services
Week in Review: Yantai's MabPlex Raises $59 Million to Expand CDMO Services
Deals and Financings
Company News
- Boehringer Ingelheim has begun an expansion of its Shanghai biologic contract manufacturing facility to prepare for commercial production;
Trials and Approvals
- Ironwood Pharma announced China approved its treatment for irritable bowel syndrome with constipation, which will be marketed in China by AstraZeneca;
- Cellular Biomedicine reported that its off-the-shelf therapy for Knee Osteoarthritis (KOA) was approved to start a China Phase II trial;
- Suzhou Innovent Biologics has dosed the first patient in a China Phase I clinical trial of its anti-CD47 mAb, an inhibitor of the "Don't Eat Me" pathway;
- BeiGene, a Beijing oncology biopharma, was granted Breakthrough Therapy designation in the US for its Bruton’s tyrosine kinase (BTK) inhibitor.
Stock Symbols: (HK; 1672) (BSE: 500087) (HK: 8126) (NYSE: AZN) (NSDQ: IRWD) (NYSE: AZN) (NSDQ: CBMG) (HK: 01801) (NSDQ: BGNE; HK: 06160)
Share this with colleagues:
More From BioPortfolio on "Week in Review: Yantai's MabPlex Raises $59 Million to Expand CDMO Services"